U.S. Futures Rise as Market Optimism Rebounds
Futures are higher this morning amid renewed optimism around the U.S.-China talks between President Trump and President Xi Jinping. Markets are extending a rebound despite another wave of inflation anxiety as investors continue favoring AI and semiconductor names over broader macro concerns.The tension in markets remains the disconnect between rising inflation and rising stocks. The April PPI report yesterday came in at its hottest level in four years, adding to this week's hotter-than-expected CPI report. Investors are increasingly discussing the possibility that the Federal Reserve may eventually need to hike rates again instead of cutting them.Bond markets are reflecting that concern. Long-term Treasury yields remain elevated, with the 30-year yield above 5% and the 10-year hovering near 4.5%. Some strategists note that the S&P 500's earnings yield is now below the 10-year Treasury yield, changing valuation dynamics for investors.What continues to overpower those concerns, however, is the AI trade. Semiconductor and infrastructure-related technology stocks remain the market's leadership group, and investors continue treating artificial intelligence spending as a secular growth wave large enough to offset inflation pressure and slower economic growth.Crude is still trading above $100 a barrel as markets monitor the Iran conflict and global supply disruptions. The International Energy Agency warned this week that global oil inventories are falling at a record pace, which has intensified stagflation concerns across markets.In pre-market trading, S&P 500 futures rose 0.30%, Nasdaq futures rose 0.13% and Dow futures rose 0.85%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Biogenup 4% after reporting topline results from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide therapy targeting tau, in individuals with early Alzheimer's diseaseNvidiaup 2% after Reutersthe U.S. has approved about 10 Chinese companies to purchase Nvidia H200 chipsUP AFTER EARNINGS -StubHubup 15%Ciscoup 14%Klarnaup 12%Yetiup 8%Viking Holdingsup 5%DOWN AFTER EARNINGS -Doximitydown 21%Enovixdown 10%Bullishdown 8%
Trade with 70% Backtested Accuracy
Analyst Views on BIIB
About BIIB
About the author

- Trial Setback: Biogen's shares fell 6.4% on May 14, 2026, after the CELIA trial data failed to meet its primary dose-response endpoint, resulting in significant losses for investors and a decline in market confidence.
- Future Development Plans: Despite the setback, Biogen intends to advance diranersen to registrational development based on biomarker and efficacy data, indicating the company's belief in the drug's long-term potential.
- Legal Investigation Initiated: Following the disappointing trial results, Levi & Korsinsky law firm has launched an investigation into Biogen, focusing on whether the company made misleading statements that could affect investors' legal rights.
- Investor Action Recommendations: Affected investors are encouraged to gather trading records and contact Levi & Korsinsky for a free evaluation to understand potential legal remedies, ensuring their rights are protected.
- Significant Stock Drop: Biogen's shares fell 6.4% on May 14, 2026, after the CELIA trial data failed to meet its primary dose-response endpoint, resulting in substantial losses for investors and reflecting a decline in market confidence regarding the company's research capabilities.
- Trial Results Disclosure: The company confirmed in its press release that the CELIA trial did not meet its primary endpoint; however, Biogen plans to advance diranersen to registrational development based on biomarker and efficacy data, indicating confidence in the drug's potential value despite the setback.
- Legal Investigation Initiated: Following the disclosure of the CELIA trial results, Levi & Korsinsky law firm has launched an investigation into Biogen, focusing on whether the company made materially false or misleading statements regarding the trial's failure, which may lead to more investors seeking legal remedies.
- Investor Action Recommendations: Affected investors are encouraged to gather trading records and contact the law firm for a free evaluation, which could provide potential compensation opportunities, further impacting the company's reputation and shareholder confidence.
- Biogen's Turnaround Potential: Biogen focuses on neurology, and despite declining revenue from its multiple sclerosis products, Q1 2025 revenue rose 2% year-over-year to $2.5 billion, with Leqembi sales increasing 74% to $168 million, indicating significant market potential in Alzheimer's treatment.
- Acquisition-Driven Pipeline Expansion: By acquiring Reata Pharmaceuticals for $7.3 billion and Apellis Pharmaceuticals for $5.6 billion, Biogen has introduced new drugs like Skyclarys and Empaveli, with projected sales growth in the low to mid-teens through 2028, enhancing its product diversity.
- Novo Nordisk's Growth Engine: Novo Nordisk excels in diabetes and obesity markets, reporting Q1 2025 revenue of 96.8 billion DKK (approximately $15.3 billion), a 24% year-over-year increase, driven by high demand for its GLP-1 drugs, prompting the company to expand manufacturing capacity for sustained competitiveness.
- Diversification Strategy: Novo Nordisk's $4.7 billion acquisition of Akero Therapeutics strengthens its metabolic treatment portfolio, while label expansions for its GLP-1 therapies in cardiovascular and chronic kidney disease treatments enhance clinical versatility, solidifying its competitive position in the healthcare insurance market.
- Clinical Trial Progress: Biogen announced its plan to advance an experimental Alzheimer's drug to Phase 3 testing despite disappointing mid-stage trial results, as it shows potential in reducing tau protein levels and slowing cognitive decline, particularly at the lowest dose.
- Drug Development Challenges: The company has faced setbacks in its Alzheimer's drug development journey, having successfully launched two drugs to slow cognitive decline, yet its first drug, Aduhelm, was withdrawn due to approval controversies, highlighting market uncertainties.
- Scientific Basis: Biogen's head of development, Dr. Priya Singhal, stated that the latest trial results demonstrate an unprecedented combination of tau reduction and cognitive benefits, emphasizing the necessity to move to Phase 3 testing, indicating progress in dose isolation.
- Competitive Landscape: In the Alzheimer's treatment arena, Biogen faces pressure from rival Eli Lilly, which is also studying drugs aimed at decreasing tau protein levels, underscoring the intense market competition and the urgent demand for innovative therapies.
- Bitcoin-Linked Stocks Rise: Bitcoin rose 2% as the Senate Banking Committee discussed a regulatory framework for cryptocurrencies, with Coinbase shares jumping nearly 9%, indicating growing market confidence that could drive future growth for related companies.
- Starbucks Upgrade: TD Cowen upgraded Starbucks from hold to buy, raising its price target from $106 to $120, with analysts noting multiple positive sales drivers in a strong market backdrop, suggesting improved performance ahead.
- Ford Stock Surge: Ford shares rose 7%, adding to a 13% gain from Wednesday, as Morgan Stanley highlighted its energy storage business and partnership with CATL, projecting a $3 billion incremental revenue opportunity for Ford's Model e segment.
- Applied Materials Earnings Outlook: Applied Materials saw a 2% increase in shares ahead of its fiscal second-quarter results, with analysts expecting earnings of $2.66 per share and revenue of $7.68 billion, reflecting sustained optimism about semiconductor equipment demand.
- Clinical Trial Progress: Biogen announced its plan to advance an experimental Alzheimer's drug into Phase 3 testing despite disappointing mid-stage results, as signals from the lowest dose suggest potential tau reduction and cognitive decline slowing, indicating the drug's development value.
- Mechanism of Action: The drug Diranersen is an antisense oligonucleotide aimed at limiting tau protein production; although higher doses did not show better responses, the efficacy at lower doses provides hope for further research and could pave the way for new Alzheimer's treatments.
- R&D Challenges and Opportunities: Biogen has faced numerous setbacks in developing Alzheimer's drugs, with its first drug Aduhelm withdrawn due to controversy, yet the company remains committed to advancing new therapies, demonstrating resilience in this challenging field.
- Competitive Landscape: As Biogen pushes forward with its drug, rival Eli Lilly is also studying drugs aimed at decreasing tau levels, highlighting the intensifying competition in Alzheimer's treatment, necessitating Biogen to accelerate its R&D efforts to maintain market leadership.











